DeuterOncology: Funding, Investors & Team (Sep 2026)
A preclinical-stage biotech startup called DeuterOncology is working to create the first dual inhibitor of the MET and RAS pathways for use in cancer treatment.
DeuterOncology has raised $6.1M across 1 funding round on record, the most recent a Series A of $6.1M announced in Jan 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
DeuterOncology Company Profile and Key Stats
Latest funding round on record: Jan 2023.
DeuterOncology Funding Rounds
DeuterOncology Founders and Leadership Team
Contact details for the DeuterOncology team: 1 of 1 has an email address on file.
Start 14-day free trial →DeuterOncology Funding Compared to Other Biotechnology Startups
DeuterOncology's latest round of $6.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like DeuterOncology in Biotechnology and Geel
Companies Similar to DeuterOncology
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
DeuterOncology Funding FAQs
What does DeuterOncology do?
A preclinical-stage biotech startup called DeuterOncology is working to create the first dual inhibitor of the MET and RAS pathways for use in cancer treatment.
How much funding has DeuterOncology raised?
DeuterOncology has raised $6.1M across 1 round on record. The most recent is a Series A of $6.1M announced in Jan 2023.
When did DeuterOncology last raise funding?
DeuterOncology's most recent funding round on record is a Series A of $6.1M, announced in Jan 2023.
Who is the CEO of DeuterOncology?
Timothy Perera is listed as CEO at DeuterOncology.
Where is DeuterOncology headquartered?
DeuterOncology is based in Geel, Antwerpen, Belgium.
How many employees does DeuterOncology have?
DeuterOncology is in the 1-10 employee band.
How does DeuterOncology's funding compare to other Biotechnology startups?
DeuterOncology's latest round of $6.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's DeuterOncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for DeuterOncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.